Research Interests Pharmacogenetic studies on the discovery of novel human genetic polymorphisms, their functional significance and their relationship to outcome of drug therapy, susceptibility to adverse drug reactions and susceptibility to complex diseases, especially those affecting the liver. These studies are central to the area of personalised (stratified) medicine and a key aim is to translate our findings to simple tests that can be used to determine the most appropriate drug treatment on an individual basis. I coordinate the iDILIC network on genetics of drug-induced liver injury (see iDILIC Description) which is concerned with identifying genes relevant to drug-induced liver injury and also participate as the UNEW PI in the IMI-FP7-funded TransBioLine project which seeks to identify novel biomarkers for serious adverse drug reactions (https://transbioline.com/). I contribute to the LITMUS project (https://litmus-project.eu/) which is also IMI-FP7-funded and to the NIAAA-funded GenomALC (see GenomALC description). These studies are concerned with identification of biomarkers for non-alcoholic fatty liver disease (NAFLD) and for alcoholic liver cirrhosis respectively.